| Sep 12 |
Innate Pharma GAAP EPS of -€0.31, revenue of €12.35M
|
| Sep 12 |
Innate Pharma Reports First Half 2024 Business Update and Financial Results
|
| Sep 9 |
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
|
| Sep 5 |
Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
|
| Sep 4 |
Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Jul 25 |
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
|
| Jun 18 |
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
|
| Jun 17 |
Innate falls on updated phase 1/2 data on blood cancer asset teamed with Sanofi
|
| Jun 17 |
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
|
| Jun 4 |
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
|
